Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Four months today
View:
Post by prophetoffactz on Mar 07, 2023 9:22am

Four months today

Four months today since the signing of the license agreement with the University of Alberta for the scale-up of PGX. Has all the required equipment been moved in and have they tried to produce the first product? Is CZO ahead of schedule for launch early next year and if it is now working effectively are they ready for al licensing deal? The financials and update are expected next month. Hopefully it is all systems go.
Comment by Ciao on Mar 07, 2023 11:17am
The PGX scale up for the go it alone Y-BG immune booster was to add about $100M to its NPV based on the Y-BG portion of the immune booster market and what CEAPRO could conservatively capture. It won't be a straight line move but as the scale up progresses to commercial production, that works out to an additional $100M ($1.25/share) to the current market cap.